TR201802944T4 - İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ - Google Patents

İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ Download PDF

Info

Publication number
TR201802944T4
TR201802944T4 TR2018/02944T TR201802944T TR201802944T4 TR 201802944 T4 TR201802944 T4 TR 201802944T4 TR 2018/02944 T TR2018/02944 T TR 2018/02944T TR 201802944 T TR201802944 T TR 201802944T TR 201802944 T4 TR201802944 T4 TR 201802944T4
Authority
TR
Turkey
Prior art keywords
same
mixture
diazaindazol
azaindazol
derivatives
Prior art date
Application number
TR2018/02944T
Other languages
English (en)
Turkish (tr)
Inventor
Bachi̇r Kaloun El
Bedjeguelal Kari̇m
Rabot Rémi̇
Kruczynski Anna
Schmitt Phi̇li̇ppe
Perez Mi̇chel
Rahier Ni̇colas
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TR201802944T4 publication Critical patent/TR201802944T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2018/02944T 2011-01-27 2012-01-27 İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ TR201802944T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Publications (1)

Publication Number Publication Date
TR201802944T4 true TR201802944T4 (tr) 2018-03-21

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/02944T TR201802944T4 (tr) 2011-01-27 2012-01-27 İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇

Country Status (30)

Country Link
US (2) US20130172360A1 (OSRAM)
EP (1) EP2668184B1 (OSRAM)
JP (1) JP5931926B2 (OSRAM)
KR (2) KR101923751B1 (OSRAM)
CN (1) CN103339129B (OSRAM)
AR (1) AR084935A1 (OSRAM)
AU (1) AU2012210467B2 (OSRAM)
BR (1) BR112013018852B1 (OSRAM)
CA (1) CA2823824C (OSRAM)
CY (1) CY1120088T1 (OSRAM)
DK (1) DK2668184T3 (OSRAM)
ES (1) ES2661695T3 (OSRAM)
FR (1) FR2970967B1 (OSRAM)
HR (1) HRP20180524T1 (OSRAM)
HU (1) HUE037153T2 (OSRAM)
IL (2) IL227496B (OSRAM)
LT (1) LT2668184T (OSRAM)
MA (1) MA34903B1 (OSRAM)
MX (1) MX356411B (OSRAM)
MY (1) MY180666A (OSRAM)
PL (1) PL2668184T3 (OSRAM)
PT (1) PT2668184T (OSRAM)
RS (1) RS57101B1 (OSRAM)
RU (1) RU2600976C2 (OSRAM)
SI (1) SI2668184T1 (OSRAM)
TN (1) TN2013000293A1 (OSRAM)
TR (1) TR201802944T4 (OSRAM)
TW (1) TWI546303B (OSRAM)
UA (1) UA109698C2 (OSRAM)
WO (1) WO2012101239A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2817292B1 (en) 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10336707B2 (en) 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112313232B (zh) * 2018-05-02 2024-03-08 Jw中外制药公司 新型杂环衍生物
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115279770A (zh) * 2019-12-31 2022-11-01 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
KR20230147036A (ko) 2020-11-20 2023-10-20 2692372 온타리오 인크. 벤젠설폰아미드 유도체 및 이의 용도
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT970084E (pt) * 1997-03-19 2003-10-31 Abbott Gmbh & Co Kg Pirrolo¬2,3d|pirimidinas e sua utilizacao como inibidores da tirosina-cinase
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
PL359651A1 (en) 2000-06-22 2004-08-23 Pfizer Inc. Process for the preparation of pyrazolopyrimidinones
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP5302896B2 (ja) 2006-12-20 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 癌治療のためのキナーゼ阻害剤としてのインダゾール誘導体
BRPI0814628B1 (pt) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
EP2668184B1 (en) 2018-01-10
IL257748A (en) 2018-04-30
IL227496A0 (en) 2013-09-30
NZ614432A (en) 2015-03-27
CY1120088T1 (el) 2018-12-12
WO2012101239A1 (en) 2012-08-02
AU2012210467A1 (en) 2013-09-12
CA2823824A1 (en) 2012-08-02
MX356411B (es) 2018-05-24
DK2668184T3 (en) 2018-03-12
EP2668184A1 (en) 2013-12-04
TW201247664A (en) 2012-12-01
BR112013018852A2 (pt) 2017-08-15
US8883821B2 (en) 2014-11-11
PT2668184T (pt) 2018-03-13
BR112013018852B1 (pt) 2021-12-21
AR084935A1 (es) 2013-07-10
UA109698C2 (xx) 2015-09-25
MY180666A (en) 2020-12-04
MX2013008673A (es) 2013-12-02
KR101923751B1 (ko) 2018-11-29
IL227496B (en) 2019-02-28
AU2012210467B2 (en) 2016-07-07
FR2970967A1 (fr) 2012-08-03
JP5931926B2 (ja) 2016-06-08
CN103339129B (zh) 2015-07-29
ES2661695T3 (es) 2018-04-03
RU2600976C2 (ru) 2016-10-27
KR20140014147A (ko) 2014-02-05
TWI546303B (zh) 2016-08-21
LT2668184T (lt) 2018-04-10
KR20180122028A (ko) 2018-11-09
US20130172360A1 (en) 2013-07-04
IL257748B (en) 2020-06-30
PL2668184T3 (pl) 2018-06-29
CA2823824C (en) 2018-12-11
RU2013138624A (ru) 2015-03-10
MA34903B1 (fr) 2014-02-01
HRP20180524T1 (hr) 2018-05-04
TN2013000293A1 (en) 2015-01-20
FR2970967B1 (fr) 2013-02-15
CN103339129A (zh) 2013-10-02
RS57101B1 (sr) 2018-06-29
SI2668184T1 (en) 2018-06-29
US20130085144A1 (en) 2013-04-04
JP2014503574A (ja) 2014-02-13
HUE037153T2 (hu) 2018-08-28
HK1186737A1 (en) 2014-03-21

Similar Documents

Publication Publication Date Title
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MX2013012588A (es) Inhibidores de cinasa.
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
BR112016016844A2 (pt) Compostos heterocíclicos
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
NZ708593A (en) Novel pyrazole derivative
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201070483A1 (ru) Новые офтальмологические композиции
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
WO2013040227A3 (en) Therapeutic compounds
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.